| 马苗苗,普拉提·努尔别克,张泽高.单药顺铂与顺铂联合吉西他滨同步放化疗治疗中晚期宫颈癌的预后分析[J].中国肿瘤,2017,26(12):995-998. |
| 单药顺铂与顺铂联合吉西他滨同步放化疗治疗中晚期宫颈癌的预后分析 |
| Efficacy and Safety of Concurrent Radiochemotherapy for Advanced Cervical Cancer: Cisplatin Monotherapy Versus Cisplatin Combined with Gemcitabine |
| 投稿时间：2017-02-15 |
| DOI：10.11735/j.issn.1004-0242.2017.12.A013 |
|
 |
| 中文关键词: 顺铂 吉西他滨 同步放化疗 宫颈肿瘤 |
| 英文关键词:cisplatin gemcitabine concurrent chemoradiotherapy cervical neoplasms |
| 基金项目:新疆少数民族科技人才特殊培养计划（2016D0230） |
|
| 摘要点击次数: 1985 |
| 全文下载次数: 645 |
| 中文摘要: |
| 摘 要：［目的］ 探讨中晚期宫颈鳞状细胞癌单药顺铂与顺铂联合吉西他滨同步放化疗的近期疗效、不良反应及生存率之间的差异。 ［方法］ 回顾分析121例宫颈鳞状细胞癌，FIGO分期为ⅡB~ⅢB期，卡氏评分≥70分。顺铂组（63例）接受外照射加锎252中子后装治疗及顺铂同步化疗；顺铂+吉西他滨组（58例）接受同样放疗及顺铂联合吉西他滨同步化疗。比较两组患者的近期疗效、不良反应及生存率。［结果］ 顺铂组近期有效（CR+PR）率为90.48%，顺铂+吉西他滨组近期有效率为91.38%，差异无统计学意义(P>0.05)；顺铂+吉西他滨组中患者不良反应中骨髓抑制、肝功能损害与顺铂组相比，差异有统计学意义(P<0.05)，其余不良反应无统计学差异；放射性肠炎和膀胱炎的发生率两组无差异；两组生存率差异无统计学意义(P>0.05)。 ［结论］ 在中晚期宫颈鳞状细胞癌的临床治疗中，对患者实施放射治疗的同时选择顺铂或顺铂联合吉西他滨的近期疗效和生存率之间无差异，联合用药增加患者的不良反应，还需探索更优的联合化疗方案。 |
| 英文摘要: |
| Abstract：［Purpose］ To compare the efficacy and safety of cisplatin monotherapy to cisplatin in combination with gemcitabine in concurrent radiochemotherapy for advanced squamous cell carcinoma of the cervix. ［Methods］ The clinical data of 121 patients with FIGO stage ⅡB~ⅢB cervical carcinoma and Karnofsky score ≥70 were analyzed retrospectively. All patients received external irradiation combined with californium-252 neutron brachytherapy and concurrent chemotherapy，among whom 63 cases received cisplatin monotherapy(cisplatin group)，and 58 cases received cisplatin and gemcitabine for chemotherapy (cisplatin+gemcitabine group). The short-term efficacy，side effects and survival rate of two groups were compared.［Results］ The short-term efficacy (CR+PR) of cisplatin and cisplatin+gemcitabine groups was 90.48%(57/63) and 91.38%(53/58)，respectively(P>0.05). The incidence of bone marrow suppression and liver damage in cisplatin+gemcitabine group was higher than that in cisplatin group(P<0.05)；while there was no difference in incidence of radiation enteritis and cystitis between two groups. There was no significant difference in survival rate between two groups(P>0.05). ［Conclusion］ There is no difference in short-term efficacy and survival between cisplatin and cisplatin combined with gemcitabine in concurrent radiochemotherapy for advanced cervical cancer，however，the combination therapy increases toxic side effects. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |